Roche EP4251614A1: N-Substituted Aniline Hepatitis B Treatment

The EPO granted patent EP4251614A1 to F. Hoffmann-La Roche AG, conferring exclusive intellectual property rights in EU-designated states for a hepatitis B virus treatment compound. The patent covers N-substituted 4-(5-phenyl-1,3,4-oxadiazol-2-yl)aniline compositions and their therapeutic applications. Four inventors are listed on the patent: LIN Xianfeng, YUN Hongying, ZHANG Bo, and ZHENG Xiufang. The patent is classified under multiple IPC codes including C07D 271/107, C07D 413/12, C07D 417/12, A61P 31/12, and various A61K pharmaceutical composition codes.

For pharmaceutical manufacturers and biotech firms, this grant signals that Roche has secured exclusive rights to this specific oxadiazole-aniline scaffold for HBV applications across EU member states. Companies developing competing hepatitis B therapeutics should review their compounds for potential overlap with the granted claims and assess freedom-to-operate implications. The patent's therapeutic use claims (A61P 31/12) indicate the hepatitis B indication is specifically protected, which may affect pipeline planning and licensing negotiations in the antiviral space.